(ARTO trial-NCT03449719): Role of local treatment after progression in patients with castrate-resistant prostate cancer undergoing first-line abiraterone treatment.

被引：0
|
作者：
Francolini, Giulio
Di Cataldo, Vanessa
Detti, Beatrice
Garlatti, Pietro
Caini, Saverio
Bruni, Alessio
Ingrosso, Gianluca
D'Angelillo, Rolando Maria
Alitto, Anna Rita
Augugliaro, Matteo
Triggiani, Luca
Parisi, Silvana
Facchini, Gaetano
Banini, Marco
Simontacchi, Gabriele
Desideri, Isacco
Meattini, Icro
Valicenti, Richard K.
Livi, Lorenzo
机构：
[1] Univ Florence, Radiat Oncol Unit, Azienda Osped Univ Careggi, Florence, Italy
[2] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy
[3] Inst Canc Res Prevent & Clin Network, Canc Risk Factors & Life Style Epidemiol Unit, Florence, Italy
[4] Univ Hosp Modena, Dept Oncol & Hematol, Radiotherapy Unit, Modena, Italy
[5] Univ Perugia, Radiat Oncol Sect, Dept Med & Surg, Perugia, Italy
[6] Univ Roma Tor Vergata, Radiat Oncol, Dept Biomed & Prevent, Rome, Italy
[7] Fdn Policlin Univ A Gemelli IRCCS, UOC Radioterapia Oncol, Dipartimento Diagnost Immagini Radioterapia Oncol, Rome, Italy
[8] Azienda USL IRCCS Reggio Emilia, Unit Radiotherapy, Reggio Emilia, Italy
[9] Univ Brescia, Dept Radiat Oncol, Brescia, Italy
[10] Univ Messina, Radiat Oncol Unit, Dept Biomed Dent Sci & Morphol & Funct Images, Messina, Italy
[11] SM Grazie Hosp, Med Oncol Unit, Naples, Italy
[12] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-137-3222-3876-5567; 130-540-543-12277-2683; 261-265; 261-566-11347; 3282-270-434-2806; 283-2494-5577-2829; 7; 5; 3; 2; 162; 175; 3617; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.130
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：130 / 130
页数：1
相关论文
共 50 条
  • [1] Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)
    Francolini, Giulio
    Bertini, Niccolo
    Di Cataldo, Vanessa
    Garlatti, Pietro
    Aquilano, Michele
    Caini, Saverio
    Bruni, Alessio
    Ingrosso, Gianluca
    D'angelillo, Rolando Maria
    Tagliaferri, Luca
    Augugliaro, Matteo
    Triggiani, Luca
    Parisi, Silvana
    Timon, Giorgia
    Arcidiacono, Fabio
    Marvaso, Giulia
    Jereczek-Fossa, Barbara Alicja
    Lancia, Andrea
    Franzese, Ciro
    Alongi, Filippo
    Simontacchi, Gabriele
    Greto, Daniela
    Bonomo, Pierluigi
    Loi, Mauro
    Frosini, Giulio
    Burchini, Luca
    Desideri, Isacco
    Meattini, Icro
    Valicenti, Richard K.
    Livi, Lorenzo
    PROSTATE CANCER AND PROSTATIC DISEASES, 2025,
  • [2] Early outcomes from a phase II randomized trial testing stereotactic body radiation therapy in patients undergoing I line treatment with abiraterone acetate for oligometastatic castration resistant prostate cancer (ARTO trial-NCT03449719)
    Francolini, G.
    Allegra, A. G.
    Caini, S.
    Detti, B.
    Di Cataldo, V.
    Alitto, A.
    Parisi, S.
    D'Angelillo, R. M.
    Bruni, A.
    Ingrosso, G.
    Timon, G.
    Burchini, L.
    Frosini, G.
    Valzano, M.
    Ganovelli, M.
    Desideri, I.
    Visani, L.
    Olmetto, E.
    Becherini, C.
    Salvestrini, V.
    Lapini, A.
    Meattini, I.
    Livi, L.
    EUROPEAN UROLOGY, 2023, 83
  • [3] Biochemical outcomes from ARTO trial (NCT03449719) a phase II randomized trial testing association between abiraterone acetate and stereotactic body radiation therapy in castrate-resistant prostate cancer patients
    Francolini, G.
    Detti, B.
    Di Cataldo, V.
    Caini, S.
    Alitto, A. R.
    Parisi, S.
    Demofonti, C.
    Bruni, A.
    Ingrosso, G.
    Timon, G.
    Allegra, A. G.
    Burchini, L.
    Salvestrini, V.
    Frosini, G.
    Cerbai, C.
    Visani, L.
    Becherini, C.
    Desideri, I.
    Meattini, I.
    Livi, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1167 - S1168
  • [4] Impact of BRCA status in patients with castrate-resistant prostate cancer undergoing abiraterone plus /- stereotactic body radiotherapy: ARTO trial.
    Francolini, Giulio
    Di Cataldo, Vanessa
    Garlatti, Pietro
    Bertini, Niccolo
    Aquilano, Michele
    Caini, Saverio
    Ingrosso, Gianluca
    Bruni, Alessio
    D'Angelillo, Rolando Maria
    Tagliaferri, Luca
    Augugliaro, Matteo
    Triggiani, Luca
    Parisi, Silvana
    Simontacchi, Gabriele
    Jereczek-Fossa, Barbara Alicja
    Alongi, Filippo
    Arcidiacono, Fabio
    Lancia, Andrea
    Scorsetti, Marta
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [5] Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer (mCRPC).
    Marar, Mallika
    Long Qi
    Mamtani, Ronac
    Narayan, Vivek
    Vapiwala, Neha
    Parikh, Ravi Bharat
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [6] ARTO trial-(NCT03449719): Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration-resistant prostate cancer undergoing I line treatment with abiraterone acetate.
    Francolini, Giulio
    Detti, Beatrice
    Di Cataldo, Vanessa
    Caini, Saverio
    Alitto, Anna Rita
    Parisi, Silvana
    Demofonti, Chiara
    Bruni, Alessio
    Ingrosso, Gianluca
    Timon, Giorgia
    Allegra, Andrea
    Aquilano, Michele
    Ciccone, Lucia Pia
    Salvestrini, Viola
    Frosini, Giulio
    Cerbai, Cecilia
    Desideri, Isacco
    Meattini, Icro
    Mangoni, Monica
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [7] Overall survival beyond first-line docetaxel in patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
    Heo, Mi Hwa
    Park, Se Hoon
    Kim, Hee Kyung
    Cho, Jinhyun
    Kim, Youjin
    Lee, Hansang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [8] Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)
    Francolini, Giulio
    Allegra, Andrea Gaetano
    Detti, Beatrice
    Di Cataldo, Vanessa
    Caini, Saverio
    Bruni, Alessio
    Ingrosso, Gianluca
    D'Angelillo, Rolando Maria
    Alitto, Anna Rita
    Augugliaro, Matteo
    Triggiani, Luca
    Parisi, Silvana
    Facchini, Gaetano
    Banini, Marco
    Simontacchi, Gabriele
    Desideri, Isacco
    Meattini, Icro
    Valicenti, Richard K.
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36) : 5561 - +
  • [9] PRIMERA trial (NCT04188275), early survival results from a prospective trial exploring impact of circulating tumor cell detection in castrate resistant prostate cancer patients undergoing abiraterone or enzalutamide I line treatment.
    Francolini, Giulio
    Loi, Mauro
    Ciccone, Lucia Pia
    Mangoni, Monica
    Detti, Beatrice
    Di Cataldo, Vanessa
    Aquilano, Michele
    Allegra, Andrea
    Pinzani, Pamela
    Salvianti, Francesca
    Cerbai, Cecilia
    Burchini, Luca
    Frosini, Giulio
    Mattioli, Chiara
    Salvestrini, Viola
    Guerrieri, Barbara
    Salvatore, Giulia
    Sottili, Mariangela
    Desideri, Isacco
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [10] Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC).
    Lee, Elizabeth K.
    Teply, Benjamin A.
    Maughan, Benjamin Louis
    Carducci, Michael Anthony
    Antonarakis, Emmanuel S.
    Denmeade, Samuel R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345